Targeted Delivery Systems for Ageing Interventions

Why Delivery Is Often the Bottleneck

Many advanced ageing interventions depend on placing a biologically active payload in the correct cells at the correct dose for the correct duration. A gene, RNA, protein, editing enzyme, senolytic payload, or reprogramming factor can look plausible in a dish while remaining impractical in a whole organism. The delivery system determines exposure: which organs receive the payload, which cell types are missed, how much accumulates in liver or spleen, whether immune responses block repeat dosing, and whether the effect can be stopped if toxicity appears.

This matters for ageing research because the target is rarely a single, isolated lesion. Ageing biology involves multiple tissues, chronic exposure histories, immune variation, and comorbid disease. A platform that works for a monogenic disease in one tissue may not be appropriate for broad age-related use.

Delivery Platforms at a Glance

AAV Tropism and Redosing Limits

AAV vectors are widely used in gene therapy because they can support long-lasting expression and some serotypes preferentially transduce particular tissues. Capsid engineering can improve transduction, alter tropism, and reduce some immune recognition, which is why AAVs appear repeatedly in gene therapy and partial reprogramming discussions. [1] [2]

The same features create problems for ageing applications. Long expression may be useful for a missing protein but risky for a payload that should be brief, such as a reprogramming factor. Payload capacity is limited, tissue targeting is incomplete, and pre-existing or induced antibodies can prevent effective redosing. High systemic doses can also create liver and immune safety concerns. For this reason, AAVs are better understood as powerful but constrained tools, not general-purpose delivery vehicles for systemic ageing interventions.

Lipid Nanoparticles and Transient RNA Delivery

Lipid nanoparticles are attractive because they can deliver RNA without integrating genetic material into the genome. For some ageing-related strategies, transient expression is a major advantage: the payload can be present for hours or days rather than months or years. LNP-mRNA delivery also has strong clinical precedent from infectious-disease vaccines and wider RNA therapeutic development. [3]

The central limitation is targeting. Many LNP formulations preferentially accumulate in the liver after systemic administration. Extrahepatic delivery to muscle, brain, heart, immune niches, or fibrotic tissue remains an active engineering problem. Ligand targeting and altered lipid chemistry can shift biodistribution in some models, but this does not yet solve the broader challenge of precise, repeatable delivery across the tissues most relevant to ageing. [4]

Extracellular Vesicles as Delivery Vehicles

Extracellular vesicles, including exosomes, are studied because cells naturally use them for intercellular communication. Their membrane composition, cargo, and source cell can influence uptake and biodistribution. This makes them relevant to stem-cell and exosome discussions, where the therapeutic claim often depends on paracrine signalling rather than durable cell engraftment. [5]

The translational challenge is control. Extracellular vesicles are heterogeneous, can be difficult to manufacture at consistent scale, may be rapidly cleared by the mononuclear phagocyte system, and do not automatically deliver a defined dose of a defined active ingredient. Recent reviews emphasize that enthusiasm for vesicle delivery needs to be balanced against unresolved reporting, loading, biodistribution, and regulatory standards. [6]

Why Ageing Makes Targeting Harder

Ageing changes the delivery environment itself. Older tissues may have altered vascular permeability, fibrosis, immune activation, reduced regenerative capacity, clonal hematopoiesis, liver disease, kidney impairment, or chronic inflammation. These factors can change pharmacokinetics, uptake, toxicity, and response. A delivery system tested in young adult animals may therefore perform differently in old animals or older humans.

This is one reason model choice matters. A convincing delivery study for ageing should ideally report age of the animals or participants, tissue biodistribution, cell-type specificity, dose, duration, immune response, off-target exposure, and functional outcomes. Without those details, it is hard to know whether a result reflects a useful ageing intervention or merely successful delivery in a favorable experimental context.

Evidence Quality and Interpretation

Confidence is high that delivery constraints are a central reason many advanced interventions fail to translate cleanly from cell culture or mice to humans. Confidence is also high that AAVs, LNPs, and extracellular vesicles each have real strengths in defined contexts. Confidence is much lower that any current platform can safely deliver multi-tissue, repeatable, tightly controlled interventions for general human ageing.

The safest interpretation is platform-specific. AAVs may be suitable when durable expression in a defined tissue is acceptable. LNPs may be suitable when transient RNA delivery is enough and the target tissue can be reached. Extracellular vesicles may be useful where their biological signalling or organotropism can be standardized. None of these assumptions should be carried over automatically to broad longevity claims.

References

1. Wang, D., Tai, P. W. L., & Gao, G. "Adeno-associated virus vector as a platform for gene therapy delivery." Nature Reviews Drug Discovery (2019). https://doi.org/10.1038/s41573-019-0012-9
2. Li, C. & Samulski, R. J. "Engineering adeno-associated virus vectors for gene therapy." Nature Reviews Genetics (2020). https://doi.org/10.1038/s41576-019-0205-4
3. Hou, X. et al. "Lipid nanoparticles for mRNA delivery." Nature Reviews Materials (2021). https://doi.org/10.1038/s41578-021-00358-0
4. Dammes, N. et al. "Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics." Nature Nanotechnology (2021). https://doi.org/10.1038/s41565-021-00928-x
5. Cheng, L. & Hill, A. F. "Therapeutically harnessing extracellular vesicles." Nature Reviews Drug Discovery (2022). https://doi.org/10.1038/s41573-022-00410-w
6. Chaudhari, A. P. et al. "The status of extracellular vesicles as drug carriers and therapeutics." Nature Reviews Bioengineering (2026). https://doi.org/10.1038/s44222-026-00405-x